slc39a1 Antibody

What is SLC39A1 and what are its primary functions in cellular physiology?

SLC39A1 (Solute carrier family 39 member 1), also known as ZIP1, is a zinc ion transport protein that mediates cellular zinc uptake. It functions as a major endogenous zinc uptake transporter in many body cells and is responsible for the rapid uptake and accumulation of physiologically effective zinc, particularly in prostate cells . SLC39A1 plays a pivotal role in maintaining zinc balance within cells and is involved in various physiological processes, including immune function, growth, and development .

The protein is part of the zinc-iron permease family and is localized to the cell membrane, where it acts as a zinc uptake transporter . Dysregulation of SLC39A1 has been associated with several pathological conditions, highlighting its importance in maintaining cellular homeostasis.

How can I confirm the specificity of my SLC39A1 antibody?

To confirm the specificity of an SLC39A1 antibody, researchers should implement multiple validation approaches:

• Western blot analysis: Perform western blotting with positive and negative control samples, looking for a band at the expected molecular weight (the human SLC39A1 protein).

• siRNA knockdown validation: Compare antibody signals between cells with normal SLC39A1 expression and those with SLC39A1 silenced using siRNA. As demonstrated in research studies, successful knockdown should show significantly reduced expression of both SLC39A1 mRNA and protein (P < 0.05) .

• Overexpression validation: Similarly, compare signals between control cells and those with SLC39A1 overexpression plasmids, which should show significantly increased SLC39A1 levels .

• Immunogen sequence analysis: Verify that the antibody was raised against a specific SLC39A1 sequence (e.g., the PACO33876 antibody is raised against recombinant Human Zinc transporter ZIP1 protein (126-179AA)) .

• Cross-reactivity testing: Test the antibody against closely related family members to ensure specificity within the SLC39 family.

What sample preparation methods are optimal for SLC39A1 antibody applications?

For optimal results when working with SLC39A1 antibodies:

For Western blot applications:

• Prepare tissue or cell lysates with RIPA buffer containing protease inhibitors

• When using the PACO33876 antibody, dilute in storage buffer (50% Glycerol, 0.01M PBS, pH 7.4)

• Include proper positive controls (tissues known to express SLC39A1)

• Ensure protein denaturation is complete before loading

For immunohistochemistry:

• Formalin-fixed, paraffin-embedded tissues should be sectioned at 4-6 μm thickness

• Heat-induced epitope retrieval methods are recommended

• Optimize blocking conditions to minimize background (typically 5-10% normal serum)

For cell culture experiments:

• When transfecting cells with SLC39A1 siRNA or overexpression plasmids, verify transfection efficiency (typically after 24-48 hours) before proceeding with antibody-based detection

How does SLC39A1 expression correlate with clinical outcomes in different cancer types?

SLC39A1 demonstrates contrasting roles across cancer types, making it a fascinating subject for cancer research:

In Gliomas:

• SLC39A1 shows upregulated expression in glioma tissues compared to paracancerous tissues

• High SLC39A1 expression predicts significantly worse survival in glioma patients

• Univariate and multivariate analyses demonstrate SLC39A1 as an independent poor prognostic indicator in glioma patients

• SLC39A1 expression correlates significantly with clinical pathological parameters including tumor grade, IDH mutation status, and 1p19q codeletion status

In Hepatocellular Carcinoma:

This dichotomous behavior underscores the tissue-specific functions of SLC39A1 and highlights the importance of context when considering it as a biomarker or therapeutic target.

What mechanisms explain SLC39A1's influence on tumor progression?

Research has revealed several mechanisms through which SLC39A1 affects tumor progression:

Proliferation and Apoptosis:

• In glioma cells, SLC39A1 overexpression significantly increases cell proliferation (P < 0.05), while SLC39A1 silencing significantly decreases proliferation (P < 0.05) as measured by CCK-8 assays

• SLC39A1 appears to inhibit apoptosis in glioma cells, with flow cytometry demonstrating increased apoptosis following SLC39A1 knockdown

Invasion and Metastasis:

• SLC39A1 significantly influences the expression of MMP2 and MMP9, key matrix metalloproteinases involved in tumor invasion

• Both mRNA and protein expression of MMP2 and MMP9 are significantly increased in SLC39A1-overexpressing cells and decreased in SLC39A1-silenced cells (P < 0.05)

Immune Microenvironment Modulation:

• SLC39A1 expression is significantly and positively correlated with ImmuneScore and StromalScore, and negatively correlated with TumorPurity in gliomas

• SLC39A1 expression shows significant positive correlation with regulatory T cells, gamma delta T cells, M0/M1/M2 macrophages, and eosinophils in the tumor microenvironment

• Conversely, SLC39A1 expression negatively correlates with naive CD4+ T cells, activated NK cells, monocytes, and activated mast cells

Pathway Involvement:

• Gene enrichment analysis reveals SLC39A1 is enriched in pathways related to extracellular matrix organization, neutrophil activation, and leukocyte migration

• KEGG analysis shows enrichment in ECM-receptor interaction, antigen processing and presentation, leukocyte transendothelial migration, and TNF signaling pathways

How can researchers best evaluate the functional consequences of SLC39A1 modulation?

To thoroughly evaluate SLC39A1 function in research settings, consider these methodological approaches:

Proliferation Analysis:

• Use Cell Counting Kit-8 (CCK-8) assays to measure cell proliferation rates following SLC39A1 silencing or overexpression

• Compare growth curves between control, SLC39A1-silenced, and SLC39A1-overexpressing cells over 24-96 hours

Apoptosis Assessment:

• Flow cytometry with Annexin V/PI staining can quantify apoptotic populations following SLC39A1 modulation

• Western blot for apoptosis markers (Bax, Bcl-2, cleaved caspase-3) provides mechanistic insights

Invasion Capability:

• RT-qPCR and western blot to measure expression of invasion-related proteins MMP2 and MMP9

• Transwell invasion assays with Matrigel to directly assess invasive capacity

Transcriptomic Analysis:

• RNA-seq to identify differentially expressed genes between high and low SLC39A1 expression groups

• GO and KEGG pathway analyses to determine enriched functions and pathways

Zinc Transport Assessment:

• Fluorescent zinc probes to measure intracellular zinc concentrations

• Radioactive zinc uptake assays to quantify transport kinetics

Immune Infiltration Analysis:

• ESTIMATE algorithm to evaluate stromal and immune cell infiltration scores

• CIBERSORT algorithm to analyze the proportions of tumor-infiltrating immune subgroups and their correlation with SLC39A1 expression

What are the optimal protocols for evaluating SLC39A1 expression in patient samples?

When investigating SLC39A1 expression in clinical specimens, consider these validated approaches:

Tissue Microarray Analysis:

• Compare SLC39A1 expression between tumor tissues and adjacent normal tissues using immunohistochemistry

• Score staining intensity (typically 0-3) and percentage of positive cells to create a composite expression score

• Correlate expression with clinicopathological features and patient outcomes

RT-qPCR Protocol for SLC39A1:

• Extract total RNA using TRIzol reagent

• Synthesize cDNA with reverse transcriptase

• Use validated SLC39A1 primers:

  • Forward: 5′-GAACAAGAGATGGTCAAGTC-3′

  • Reverse: 5′-ATGTGAGCCTGTCCTTATG-3′

• Use GAPDH as internal control:

  • Forward: 5′-GAAGGTGAAGGTCGGAGTC-3′

  • Reverse: 5′-GAAGATGGTGATGGGATTTC-3′

• Calculate relative expression using the 2-ΔΔCt method

Western Blot Analysis:

• Extract proteins with RIPA buffer containing protease inhibitors

• Separate proteins on 10% SDS-PAGE and transfer to PVDF membranes

• Block with 5% non-fat milk

• Incubate with primary SLC39A1 antibody (e.g., PACO33876)

• Detect using HRP-conjugated secondary antibodies and enhanced chemiluminescence

What experimental controls are critical when studying SLC39A1 function?

Essential Controls for SLC39A1 Research:

For gene silencing experiments:

• Negative control siRNA (non-targeting sequence)

• Positive control siRNA (targeting a housekeeping gene)

• Verification of knockdown efficiency by RT-qPCR and western blot

For overexpression studies:

• Empty vector control

• Verification of overexpression by RT-qPCR and western blot

• Rescue experiments to confirm specificity of observed phenotypes

For zinc transport studies:

• Zinc-free media controls

• Competitive inhibitors of zinc transport

• Chelation controls (TPEN or similar zinc chelators)

For patient sample analysis:

• Adjacent normal tissue controls

• Correlation with established clinical parameters (grade, stage, etc.)

• Multivariate analysis to control for confounding factors

How should researchers address the contrasting roles of SLC39A1 across different cancer types?

The contrasting roles of SLC39A1 in different cancer types present a fascinating research challenge. Here's a methodological framework to address this complexity:

Comparative Expression Analysis:

• Perform multi-cancer type analysis using public databases (TCGA, CGGA, GEO)

• Compare SLC39A1 expression patterns across cancer types and corresponding normal tissues

• Generate a comprehensive expression profile table showing upregulation/downregulation patterns

Context-Dependent Function Investigation:

• Tissue microenvironment analysis:

  • Characterize zinc concentrations in different tumor microenvironments

  • Analyze expression of other zinc transporters that might compensate for or interact with SLC39A1

• Interaction network mapping:

  • Identify tissue-specific interaction partners of SLC39A1

  • Investigate differences in downstream signaling cascades across tissue types

• Genetic and epigenetic regulation:

  • Analyze promoter methylation patterns of SLC39A1 across cancer types

  • Investigate microRNA regulation differences

  • Examine genetic alterations (mutations, copy number variations) affecting SLC39A1

Experimental Validation:

• Establish parallel in vitro models from multiple cancer types

• Perform identical SLC39A1 modulation experiments across these models

• Conduct cross-cancer xenograft studies with SLC39A1 manipulation

This approach allows researchers to systematically characterize the dichotomous behavior of SLC39A1 across cancer types, potentially revealing tissue-specific regulatory mechanisms that could inform more precise therapeutic strategies.

What are common technical issues when working with SLC39A1 antibodies and how can they be resolved?

Common Technical Challenges and Solutions:

How can researchers effectively investigate the relationship between SLC39A1 and immune infiltration?

Based on published methodologies , researchers can investigate SLC39A1-immune cell relationships using:

Computational Approaches:

• ESTIMATE algorithm:

  • Apply to RNA-seq data to generate ImmuneScore, StromalScore, and ESTIMATEScore

  • Calculate TumorPurity based on these scores

  • Determine correlation coefficients between scores and SLC39A1 expression

• CIBERSORT algorithm:

  • Apply to RNA-seq data to determine proportions of 22 immune cell subgroups

  • Calculate correlation between each immune cell type and SLC39A1 expression

  • Generate correlation heatmaps to visualize relationships

Experimental Validation:

• Multiplex immunofluorescence:

  • Co-stain for SLC39A1 and immune cell markers

  • Quantify spatial relationships between SLC39A1+ cells and immune cells

• Flow cytometry:

  • Isolate tumor-infiltrating lymphocytes (TILs) from fresh tumor samples

  • Compare immune cell composition between SLC39A1-high and SLC39A1-low tumors

• In vitro co-culture:

  • Establish co-culture systems with SLC39A1-modulated tumor cells and immune cells

  • Assess immune cell activation, cytokine production, and cytotoxicity

• Single-cell RNA sequencing:

  • Perform scRNA-seq on tumor samples

  • Analyze correlation between SLC39A1 expression and immune cell markers at single-cell resolution

What complementary approaches should be used to validate SLC39A1's role in cancer progression?

A multi-layered validation approach is essential for establishing SLC39A1's role in cancer:

In vitro validation:

• Cell proliferation assays (CCK-8)

• Apoptosis assessment (flow cytometry)

• Migration and invasion assays

• Molecular marker assessment (MMP2/MMP9 expression)

• Zinc transport measurements

In vivo validation:

• Xenograft models with SLC39A1 overexpression or knockdown

• Patient-derived xenografts from tumors with varying SLC39A1 expression

• Metastasis models to assess invasive capacity

Clinical correlation:

• Tissue microarray analysis from large patient cohorts

• Correlation with clinical parameters and survival outcomes

• Multivariate Cox regression analysis to determine independent prognostic value

Multi-omics integration:

• Correlate SLC39A1 expression with mutational landscapes

• Integrate with methylation data

• Analyze protein interaction networks using proteomics

Mechanistic studies:

• Pathway inhibition experiments to verify signaling mechanisms

• Chromatin immunoprecipitation to identify transcriptional targets

• Protein interaction studies to identify binding partners

What are promising therapeutic approaches targeting SLC39A1 in cancer?

Based on the contrasting roles of SLC39A1 across cancer types, therapeutic strategies should be tailored accordingly:

For cancers with SLC39A1 overexpression (e.g., gliomas):

• Small molecule inhibitors of SLC39A1 transport function

• siRNA or antisense oligonucleotide delivery systems for SLC39A1 knockdown

• Monoclonal antibodies targeting SLC39A1 extracellular domain

• Combination therapy with MMP2/MMP9 inhibitors to target downstream invasion mechanisms

• Immunotherapy approaches leveraging SLC39A1's relationship with immune infiltration

For cancers with SLC39A1 downregulation (e.g., EHCC):

• Gene therapy approaches to restore SLC39A1 expression

• Zinc supplementation strategies for targeted delivery to tumor cells

• Drugs targeting compensatory zinc transport mechanisms

• Biomarker-driven patient stratification for personalized treatment

Novel approaches:

• CRISPR-based gene editing to modify SLC39A1 expression

• Zinc ionophores with selective activity in SLC39A1-deficient cells

• Nanoparticle-based targeted delivery systems

• Bifunctional molecules linking SLC39A1 to ubiquitin ligases for targeted degradation

How might genomic and proteomic approaches further elucidate SLC39A1 function?

Advanced -omics approaches offer powerful tools for deeper investigation of SLC39A1:

Genomic approaches:

• Whole genome/exome sequencing to identify SLC39A1 mutations and their functional consequences

• CRISPR screens to identify synthetic lethal interactions with SLC39A1

• ChIP-seq to map transcription factors regulating SLC39A1 expression

• Hi-C to analyze three-dimensional genome organization around the SLC39A1 locus

Transcriptomic approaches:

• Single-cell RNA-seq to characterize cell-type specific SLC39A1 expression patterns

• Spatial transcriptomics to map SLC39A1 expression within the tumor microenvironment

• RNA-binding protein immunoprecipitation to identify post-transcriptional regulators

Proteomic approaches:

• Proximity labeling (BioID, APEX) to identify SLC39A1 interaction partners

• Phosphoproteomics to characterize signaling cascades affected by SLC39A1

• Metalloproteomics to identify zinc-binding proteins affected by SLC39A1 activity

• Structural studies (cryo-EM, X-ray crystallography) to elucidate SLC39A1 transport mechanism

These approaches would provide multi-dimensional insights into SLC39A1 biology, facilitating more precise therapeutic targeting and biomarker development.